FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107170841> ?p ?o ?g. }

• W2107170841 endingPage "306" @default.
• W2107170841 startingPage "296" @default.
• W2107170841 abstract "Anemia, defined as a hemoglobin level of less than 12 g/dL, often is seen in congestive heart failure (CHF). It is associated with an increased mortality and morbidity and increased hospitalizations. Compared with nonanemic patients the presence of anemia also is associated with worse cardiac clinical status, more severe systolic and diastolic dysfunction, a higher beta natriuretic peptide level, increased extracellular and plasma volume, a more rapid deterioration of renal function, a lower quality of life, and increased medical costs. The only way to determine if anemia is merely a marker for more severe CHF or actually is contributing to the worsening of the CHF is to correct the anemia and see if this favorably influences the CHF. In several controlled and uncontrolled studies, correction of the anemia with subcutaneous erythropoietin (EPO) or darbepoetin in conjunction with oral and intravenous iron has been associated with an improvement in clinical status, number of hospitalizations, cardiac and renal function, and quality of life. However, larger, randomized, double-blind, controlled studies still are needed to verify these initial observations. The effect of EPO may be related partly to its nonhematologic functions including neovascularization; prevention of apoptosis of endothelial, myocardial, cerebral, and renal cells; increase in endothelial progenitor cells; and anti-inflammatory and antioxidant effects. Anemia also may play a role in increasing cardiovascular morbidity in chronic kidney insufficiency, diabetes, renal transplantation, asymptomatic left ventricular dysfunction, left ventricular hypertrophy, acute coronary syndromes including myocardial infarction and chronic coronary heart disease, and in cardiac surgery. Again, controlled studies of correction of anemia are needed to assess its importance in these conditions. The anemia in CHF mainly is caused by a combination of renal failure and CHF-induced increased cytokine production, and these can both lead to reduced production of EPO, resistance of the bone marrow to EPO stimulation, and to cytokine-induced iron-deficiency anemia caused by reduced intestinal absorption of iron and reduced release of iron from iron stores. The use of angiotensin-converting enzyme inhibitor and angiotensin receptor blockers also may inhibit the bone marrow response to EPO. Hemodilution caused by CHF also may cause a low hemoglobin level. Renal failure, cardiac failure, and anemia therefore all interact to cause or worsen each other—the so-called cardio-renal-anemia syndrome. Adequate treatment of all 3 conditions will slow down the progression of both the CHF and the chronic kidney insufficiency. Anemia, defined as a hemoglobin level of less than 12 g/dL, often is seen in congestive heart failure (CHF). It is associated with an increased mortality and morbidity and increased hospitalizations. Compared with nonanemic patients the presence of anemia also is associated with worse cardiac clinical status, more severe systolic and diastolic dysfunction, a higher beta natriuretic peptide level, increased extracellular and plasma volume, a more rapid deterioration of renal function, a lower quality of life, and increased medical costs. The only way to determine if anemia is merely a marker for more severe CHF or actually is contributing to the worsening of the CHF is to correct the anemia and see if this favorably influences the CHF. In several controlled and uncontrolled studies, correction of the anemia with subcutaneous erythropoietin (EPO) or darbepoetin in conjunction with oral and intravenous iron has been associated with an improvement in clinical status, number of hospitalizations, cardiac and renal function, and quality of life. However, larger, randomized, double-blind, controlled studies still are needed to verify these initial observations. The effect of EPO may be related partly to its nonhematologic functions including neovascularization; prevention of apoptosis of endothelial, myocardial, cerebral, and renal cells; increase in endothelial progenitor cells; and anti-inflammatory and antioxidant effects. Anemia also may play a role in increasing cardiovascular morbidity in chronic kidney insufficiency, diabetes, renal transplantation, asymptomatic left ventricular dysfunction, left ventricular hypertrophy, acute coronary syndromes including myocardial infarction and chronic coronary heart disease, and in cardiac surgery. Again, controlled studies of correction of anemia are needed to assess its importance in these conditions. The anemia in CHF mainly is caused by a combination of renal failure and CHF-induced increased cytokine production, and these can both lead to reduced production of EPO, resistance of the bone marrow to EPO stimulation, and to cytokine-induced iron-deficiency anemia caused by reduced intestinal absorption of iron and reduced release of iron from iron stores. The use of angiotensin-converting enzyme inhibitor and angiotensin receptor blockers also may inhibit the bone marrow response to EPO. Hemodilution caused by CHF also may cause a low hemoglobin level. Renal failure, cardiac failure, and anemia therefore all interact to cause or worsen each other—the so-called cardio-renal-anemia syndrome. Adequate treatment of all 3 conditions will slow down the progression of both the CHF and the chronic kidney insufficiency." @default.
• W2107170841 created "2016-06-24" @default.
• W2107170841 creator A5015324992 @default.
• W2107170841 creator A5033989831 @default.
• W2107170841 creator A5050719755 @default.
• W2107170841 creator A5079286108 @default.
• W2107170841 date "2006-07-01" @default.
• W2107170841 modified "2023-10-04" @default.
• W2107170841 title "The Interaction Between Heart Failure and Other Heart Diseases, Renal Failure, and Anemia" @default.
• W2107170841 cites W1485344637 @default.
• W2107170841 cites W1602352030 @default.
• W2107170841 cites W1964336609 @default.
• W2107170841 cites W1968364422 @default.
• W2107170841 cites W1970702365 @default.
• W2107170841 cites W1972975199 @default.
• W2107170841 cites W1977731938 @default.
• W2107170841 cites W1977907008 @default.
• W2107170841 cites W1978265501 @default.
• W2107170841 cites W1983310674 @default.
• W2107170841 cites W1983495736 @default.
• W2107170841 cites W1987016701 @default.
• W2107170841 cites W1988495648 @default.
• W2107170841 cites W1993104550 @default.
• W2107170841 cites W2001548464 @default.
• W2107170841 cites W2008112861 @default.
• W2107170841 cites W2013009184 @default.
• W2107170841 cites W2015738659 @default.
• W2107170841 cites W2021915768 @default.
• W2107170841 cites W2023792251 @default.
• W2107170841 cites W2024074211 @default.
• W2107170841 cites W2024891464 @default.
• W2107170841 cites W2025970694 @default.
• W2107170841 cites W2028628328 @default.
• W2107170841 cites W2031731549 @default.
• W2107170841 cites W2037754909 @default.
• W2107170841 cites W2038774050 @default.
• W2107170841 cites W2047589973 @default.
• W2107170841 cites W2048471256 @default.
• W2107170841 cites W2052963990 @default.
• W2107170841 cites W2054187497 @default.
• W2107170841 cites W2059023556 @default.
• W2107170841 cites W2059318691 @default.
• W2107170841 cites W2059698794 @default.
• W2107170841 cites W2060110420 @default.
• W2107170841 cites W2063247952 @default.
• W2107170841 cites W2065544460 @default.
• W2107170841 cites W2065629260 @default.
• W2107170841 cites W2067988311 @default.
• W2107170841 cites W2068120642 @default.
• W2107170841 cites W2068877594 @default.
• W2107170841 cites W2073115982 @default.
• W2107170841 cites W2073539957 @default.
• W2107170841 cites W2074192941 @default.
• W2107170841 cites W2077825559 @default.
• W2107170841 cites W2078272044 @default.
• W2107170841 cites W2080290851 @default.
• W2107170841 cites W2081127913 @default.
• W2107170841 cites W2087401679 @default.
• W2107170841 cites W2087590270 @default.
• W2107170841 cites W2088466196 @default.
• W2107170841 cites W2090136581 @default.
• W2107170841 cites W2091271949 @default.
• W2107170841 cites W2091744415 @default.
• W2107170841 cites W2093510859 @default.
• W2107170841 cites W2095440104 @default.
• W2107170841 cites W2096750760 @default.
• W2107170841 cites W2097386729 @default.
• W2107170841 cites W2097949483 @default.
• W2107170841 cites W2100587643 @default.
• W2107170841 cites W2105940225 @default.
• W2107170841 cites W2106135029 @default.
• W2107170841 cites W2106453597 @default.
• W2107170841 cites W2108417028 @default.
• W2107170841 cites W2108947052 @default.
• W2107170841 cites W2111222598 @default.
• W2107170841 cites W2112166008 @default.
• W2107170841 cites W2114587126 @default.
• W2107170841 cites W2119240491 @default.
• W2107170841 cites W2119284054 @default.
• W2107170841 cites W2122817227 @default.
• W2107170841 cites W2124839834 @default.
• W2107170841 cites W2125078410 @default.
• W2107170841 cites W2126574554 @default.
• W2107170841 cites W2131258582 @default.
• W2107170841 cites W2131701042 @default.
• W2107170841 cites W2132072950 @default.
• W2107170841 cites W2133511191 @default.
• W2107170841 cites W2134113483 @default.
• W2107170841 cites W2135844589 @default.
• W2107170841 cites W2136002054 @default.
• W2107170841 cites W2138920166 @default.
• W2107170841 cites W2141767690 @default.
• W2107170841 cites W2141955145 @default.
• W2107170841 cites W2142441226 @default.
• W2107170841 cites W2144061653 @default.
• W2107170841 cites W2145521414 @default.
• W2107170841 cites W2147319204 @default.
• W2107170841 cites W2152753934 @default.

• next